1310348-31-2

Basic information

• Product Name: 5-chloro-pyrazine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
• Synonyms: 5-chloro-pyrazine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
• CAS NO: 1310348-31-2
• Molecular Weight: 399.76
• Mol File: 1310348-31-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-chloro-pyrazine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-pyrazine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide(1310348-31-2)
• EPA Substance Registry System: 5-chloro-pyrazine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide(1310348-31-2)

Safety Data

• Hazardous Substances Data: 1310348-31-2(Hazardous Substances Data)

Upstream product

• 1310350-22-1 (R)-5,5-difluoro-4-(2-fluoro-5-nitrophenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine 
• 1075230-62-4 (R)-2-methylpropane-2-sulfinic acid [1-(2-fluoro-5-nitrophenyl)-(E)-ethylidene]amide 
• 1075231-04-7 (R)-3-amino-2,2-difluoro-3-(2-fluoro-5-nitrophenyl)butan-1-ol 
• 1075231-03-6 (R)-2-methylpropane-2-sulfinic acid [(R)-2,2-difluoro-1-(2-fluoro-5-nitrophenyl)-3-hydroxy-1-methylpropyl]amide 
• 1075231-02-5 (R)-2,2-difluoro-3-(2-fluoro-5-nitrophenyl)-3-((R)-2-methylpropane-2-sulfinylamino)butyric acid ethyl ester 
• 33332-25-1 methyl 5-chloropyrazine-2-carboxylate 
• 79110-05-7 1-(2-fluoro-5-nitrophenyl)ethanone 
• 1310350-45-8 (R)-4-(5-amino-2-fluorophenyl)-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine 
• 36070-80-1 5-chloropyrazinoic acid 

Downstream Products

• 1415914-09-8 ((R)-4-{5-[(5-chloro-pyrazine-2-carbonyl)-amino]-2-fluoro-phenyl}-5,5-difluoro-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl)-carbamic acid tert-butyl ester 
• 1415914-10-1 ((R)-5,5-difluoro-4-{2-fluoro-5-[(5-prop-2-ynyloxy-pyrazine-2-carbonyl)-amino]-phenyl}-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl)-carbamic acid tert-butyl ester 
• 1415914-11-2 (R)-N-(3-(2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-(prop-2-ynyloxy)pyrazine-2-carboxamide 
• 1415914-12-3 (R)-N-(3-(2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-(3-(tributylstannyl)prop-2-ynyloxy)pyrazine-2-carboxamide 

Relevant articles and documents

[1,3]OXAZINES

The present invention provides compounds of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer?s disease and type 2 diabetes. The invention further provides a radio-labelled derivative thereof

2-AMINO-5, 5-DIFLUORO-5, 6-DIHYDRO-4H-OXAZINES AS BACE 1 AND/OR BACE 2 INHIBITORS

The present invention relates to 2-Amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)- phenyl]-amide derivatives of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as